[go: up one dir, main page]

YU33700A - Kombinacija efikasna u tretiranju impotencije - Google Patents

Kombinacija efikasna u tretiranju impotencije

Info

Publication number
YU33700A
YU33700A YU33700A YU33700A YU33700A YU 33700 A YU33700 A YU 33700A YU 33700 A YU33700 A YU 33700A YU 33700 A YU33700 A YU 33700A YU 33700 A YU33700 A YU 33700A
Authority
YU
Yugoslavia
Prior art keywords
treatment
impotence
combination effective
compounds selected
levels
Prior art date
Application number
YU33700A
Other languages
English (en)
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22090927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU33700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU33700A publication Critical patent/YU33700A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na farmaceutske preparate, koji sadrže (1) jedinjenja koja su odabrana izmedju antagonista α-adrenergičnog receptora i (2) jedinjenja koja su odabrana izmedju agenasa koji podižu cGMP nivoe, za tretiranje erektilne disfunkcije. Sildenafil ili njegova farmaceutski prihvatljiva so je poželjan kao agens za podizanje cGMP PDE nivoa. Takodje su obuhvaćeni i preparati i pribori koji obuhvataju takva jedinjenja za tretiranje impotencije.
YU33700A 1997-12-16 1998-10-29 Kombinacija efikasna u tretiranju impotencije YU33700A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6974197P 1997-12-16 1997-12-16

Publications (1)

Publication Number Publication Date
YU33700A true YU33700A (sh) 2004-05-12

Family

ID=22090927

Family Applications (1)

Application Number Title Priority Date Filing Date
YU33700A YU33700A (sh) 1997-12-16 1998-10-29 Kombinacija efikasna u tretiranju impotencije

Country Status (37)

Country Link
EP (1) EP1037616B1 (sh)
JP (2) JP2002508315A (sh)
KR (1) KR20010033092A (sh)
CN (1) CN1282248A (sh)
AP (1) AP915A (sh)
AR (1) AR016433A1 (sh)
AT (1) ATE318602T1 (sh)
AU (1) AU759825B2 (sh)
BG (1) BG104528A (sh)
BR (1) BR9813699A (sh)
CA (1) CA2314993A1 (sh)
CO (1) CO4810381A1 (sh)
CZ (1) CZ20002199A3 (sh)
DE (1) DE69833671T2 (sh)
DZ (1) DZ2675A1 (sh)
EA (1) EA200000526A1 (sh)
ES (1) ES2258300T3 (sh)
GT (1) GT199800177A (sh)
HN (1) HN1998000174A (sh)
HR (1) HRP20000407A2 (sh)
HU (1) HUP0100705A3 (sh)
IL (1) IL136515A0 (sh)
IS (1) IS5504A (sh)
MA (1) MA26586A1 (sh)
NO (1) NO20003065L (sh)
NZ (1) NZ504487A (sh)
OA (1) OA11423A (sh)
PA (1) PA8462801A1 (sh)
PE (1) PE20000011A1 (sh)
PL (1) PL341575A1 (sh)
SK (1) SK8782000A3 (sh)
TN (1) TNSN98227A1 (sh)
TR (1) TR200001733T2 (sh)
UY (1) UY25300A1 (sh)
WO (1) WO1999030697A2 (sh)
YU (1) YU33700A (sh)
ZA (1) ZA9811507B (sh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19844162A1 (de) * 1998-09-25 2000-03-30 Udo Dunzendorfer Medikamentenkombinationen zur Therapie der erektilen Dysfunktion
CA2362918A1 (en) * 1999-03-08 2000-09-14 Elizabeth Stoner Methods and compositions for treating erectile dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
EP1200091B1 (en) * 1999-08-03 2008-07-02 Lilly Icos LLC Pharmaceutical composition comprising tadalafil
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
AU2002223802A1 (en) * 2000-11-17 2002-05-27 Warner-Lambert Company Llc Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101781302B (zh) * 2009-05-31 2013-07-10 段波 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2903619B1 (en) 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878182B (en) * 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
EP0459666B1 (en) * 1990-05-31 1994-11-09 Pfizer Inc. Medicaments against impotence
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
PL341575A1 (en) 2001-04-23
SK8782000A3 (en) 2002-03-05
CA2314993A1 (en) 1999-06-24
HUP0100705A2 (hu) 2001-08-28
CN1282248A (zh) 2001-01-31
OA11423A (en) 2004-04-21
TNSN98227A1 (fr) 2005-03-15
HN1998000174A (es) 1999-01-08
AP915A (en) 2000-12-18
NO20003065L (no) 2000-08-15
HUP0100705A3 (en) 2001-12-28
IL136515A0 (en) 2001-06-14
EP1037616B1 (en) 2006-03-01
KR20010033092A (ko) 2001-04-25
DE69833671D1 (de) 2006-04-27
ES2258300T3 (es) 2006-08-16
CZ20002199A3 (cs) 2001-10-17
ATE318602T1 (de) 2006-03-15
JP2007332156A (ja) 2007-12-27
MA26586A1 (fr) 2004-12-20
DE69833671T2 (de) 2006-11-30
PA8462801A1 (es) 2000-05-24
WO1999030697A2 (en) 1999-06-24
CO4810381A1 (es) 1999-06-30
HRP20000407A2 (en) 2000-10-31
ZA9811507B (en) 2000-06-19
WO1999030697A3 (en) 1999-08-26
DZ2675A1 (fr) 2003-03-29
NO20003065D0 (no) 2000-06-15
AU759825B2 (en) 2003-05-01
EA200000526A1 (ru) 2000-12-25
IS5504A (is) 2000-05-19
UY25300A1 (es) 2000-12-29
AP9801414A0 (en) 1998-12-31
JP2002508315A (ja) 2002-03-19
BG104528A (en) 2001-02-28
AU9455898A (en) 1999-07-05
AR016433A1 (es) 2001-07-04
NZ504487A (en) 2002-11-26
BR9813699A (pt) 2000-10-10
TR200001733T2 (tr) 2000-11-21
EP1037616A2 (en) 2000-09-27
GT199800177A (es) 2000-05-02
PE20000011A1 (es) 2000-01-18

Similar Documents

Publication Publication Date Title
YU33700A (sh) Kombinacija efikasna u tretiranju impotencije
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
EA200200208A1 (ru) Синергитическая композиция
MD809C2 (ro) (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
ES2177112T3 (es) Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
EP1615914A4 (en) CGRP RECEPTOR ANTAGONISTS
DE60216745D1 (de) Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion
PA8495101A1 (es) Derivados de 13-metileritromicina
NZ334954A (en) Substituted heterocycles as anti-tumor agents
CY1115687T1 (el) Ενωσεις για θεραπεια ανικανοτητας
BR0004538A (pt) Combinação eficaz para o tratamento da impotência
BR9809848A (pt) Composição
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
NZ530587A (en) Diazacycloalkanes as oxytocin agonists
EP0758312A4 (en) SUBSTITUTED CONDENSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS
MY139385A (en) Benzimidazoles that are useful in treating sexual dysfunction
ECSP982789A (es) Combinacion eficaz para el tratamiento de la impotencia
LV12459A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai